| Literature DB >> 32055240 |
Tuanwei Sun1,2, Dawei Jiang1,2, Zachary T Rosenkrans3, Emily B Ehlerding2, Dalong Ni2, Chao Qi1, Christopher J Kutyreff2, Todd E Barnhart2, Jonathan W Engle2, Peng Huang1, Weibo Cai2,3,4.
Abstract
Acute kidney injury (AKI) is frequently associated with oxidative stress and causes high mortality annually in clinics. Nanotechnology-mediated antioxidative therapy is emerging as a novel strategy for the treatment of AKI. Herein, a novel biomedical use of the endogenous biopolymer melanin as a theranostic natural antioxidant defense nanoplatform for AKI is reported. In this study, ultrasmall Mn2+-chelated melanin (MMP) nanoparticles are easily prepared via a simple coordination and self-assembly strategy, and further incorporated with polyethylene glycol (MMPP). In vitro experiments reveal the ability of MMPP nanoparticles to scavenge multiple toxic reactive oxygen species (ROS) and suppress ROS-induced oxidative stress. Additionally, in vivo results from a murine AKI model demonstrate preferential renal uptake of MMPP nanoparticles and a subsequent robust antioxidative response with negligible side effects according to positron emission tomography/magnetic resonance (PET/MR) bimodal imaging and treatment assessment. These results indicate that the effectiveness of MMPP nanoparticles for treating AKI suggests the potential efficacy of melanin as a natural theranostic antioxidant nanoplatform for AKI, as well as other ROS-related diseases.Entities:
Keywords: Nanotherapy for acute kidney injury; acute kidney injury; melanin nanoparticles; natural antioxidant; reactive oxygen species; theranostics
Year: 2019 PMID: 32055240 PMCID: PMC7017599 DOI: 10.1002/adfm.201904833
Source DB: PubMed Journal: Adv Funct Mater ISSN: 1616-301X Impact factor: 18.808